Xenetic Biosciences (XBIO) Gains from Investment Securities (2015 - 2017)
Xenetic Biosciences' (XBIO) quarterly Gains from Investment Securities came in at -$80560.0 in Q2 2017, down 105.89% YoY from $1.4 million in Q2 2016, and down 424.96% on a QoQ basis from -$15346.0 in Q1 2017.
Xenetic Biosciences (XBIO) Gains from Investment Securities (2015 - 2017) Analysis & Trends
Xenetic Biosciences (XBIO) has 3 years of Gains from Investment Securities data on file, last reported at -$80560.0 in Q2 2017.
- Quarterly Gains from Investment Securities fell 105.89% year-over-year to -$80560.0 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was -$93082.0 (down 104.75% YoY) and the FY2016 annual result came in at $1.1 million, up 20.17% from the prior year.
- Gains from Investment Securities declined to -$80560.0 in Q2 2017, from -$15346.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q2 2016 to a low of -$249218.0 in Q1 2016.
- A 3-year average of $217639.4 and a median of $4614.0 in 2016 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2016 — Gains from Investment Securities soared 1375.53% — and 2017, when it sank 105.89%.
- Tracing XBIO's Gains from Investment Securities over 3 years: stood at $514369.0 in 2015, then tumbled by 99.1% to $4614.0 in 2016, then tumbled by 1845.99% to -$80560.0 in 2017.
- The last three Gains from Investment Securities figures came in at -$80560.0 (Q2 2017), -$15346.0 (Q1 2017), and $4614.0 (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -80,560.00 |
| Jun 30, 2017 | -80,560.00 |
| Mar 31, 2017 | -15,346.00 |
| Mar 31, 2017 | -15,346.00 |
| Dec 31, 2016 | 4,614.00 |
| Dec 31, 2016 | 4,614.00 |
| Sep 30, 2016 | -1,790.00 |
| Sep 30, 2016 | -1,790.00 |
| Jun 30, 2016 | 1.37 Mn |
| Jun 30, 2016 | 1.37 Mn |
| Mar 31, 2016 | -249,218.00 |
| Mar 31, 2016 | -249,218.00 |
| Dec 31, 2015 | 514,369.00 |
| Dec 31, 2015 | 514,369.00 |
| Sep 30, 2015 | 326,123.00 |
| Sep 30, 2015 | 326,123.00 |
| Jun 30, 2015 | 92,703.00 |
| Jun 30, 2015 | 92,703.00 |